Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolina Säll

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 16, 2021
<i>In</i> <i>vitro</i> drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymesCarolina Säll, Christian Fogt Hjorth
Journal of Pharmaceutical Sciences|June 26, 2023
In Vitro Interaction of Tetrahydrouridine with Key Human Nucleoside TransportersCarolina Säll, Gábor Koncsos, Anna Klukovits
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 28, 2012
A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearanceCarolina Säll, J Brian Houston, Aleksandra Galetin
Pharmaceutical Research|March 14, 2014
Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction riskMichael Gertz, Nikolaos Tsamandouras, Carolina Säll, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 4, 2014
Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich cultureLassina Badolo, Bente Jensen, Carolina Säll, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 9, 2022
<b></b>Carolina Säll, Lene Alifrangis, Kirsten Dahl, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2012
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4Howard J Burt, Henry Pertinez, Carolina Säll, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 5, 2023
Evaluating Drug-Drug Interaction Risk Associated with Peptide Analogs Using advanced In Vitro SystemsRune Aa Nørgaard, Deepak K Bhatt, Erkka Järvinen, et al.
Clinical Pharmacology and Therapeutics|January 12, 2023
Industry Perspective on Therapeutic Peptide Drug-Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White PaperCarolina Säll, Upendra Argikar, Kari Fonseca, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 19, 2025
Application of a mouse model humanized for cytochrome P450-mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugsYury Kapelyukh, Charlotte Gabel-Jensen, Alastaire Kenneth MacLeod, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 16, 2021
<i>In</i> <i>vitro</i> drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymesCarolina Säll, Christian Fogt Hjorth
Journal of Pharmaceutical Sciences|June 26, 2023
In Vitro Interaction of Tetrahydrouridine with Key Human Nucleoside TransportersCarolina Säll, Gábor Koncsos, Anna Klukovits
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 28, 2012
A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearanceCarolina Säll, J Brian Houston, Aleksandra Galetin
Pharmaceutical Research|March 14, 2014
Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction riskMichael Gertz, Nikolaos Tsamandouras, Carolina Säll, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 4, 2014
Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich cultureLassina Badolo, Bente Jensen, Carolina Säll, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 9, 2022
<b></b>Carolina Säll, Lene Alifrangis, Kirsten Dahl, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2012
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4Howard J Burt, Henry Pertinez, Carolina Säll, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 5, 2023
Evaluating Drug-Drug Interaction Risk Associated with Peptide Analogs Using advanced In Vitro SystemsRune Aa Nørgaard, Deepak K Bhatt, Erkka Järvinen, et al.
Clinical Pharmacology and Therapeutics|January 12, 2023
Industry Perspective on Therapeutic Peptide Drug-Drug Interaction Assessments During Drug Development: A European Federation of Pharmaceutical Industries and Associations White PaperCarolina Säll, Upendra Argikar, Kari Fonseca, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 19, 2025
Application of a mouse model humanized for cytochrome P450-mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugsYury Kapelyukh, Charlotte Gabel-Jensen, Alastaire Kenneth MacLeod, et al.
Pageof 2